Tan Chun Bing, J. Y., et al.. XELOX + Bevacizumab Compared to FOLFOX4 + Bevacizumab in First Line Metastatic Colorectal Cancer in a Non-reimbursed Health Care System: A Cost Analysis. University of the Philippines Manila, June 2015, doi:10.47895/amp.v49i2.988.